NCI Rejects NSABP's P-4 Prevention Trial

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 7
Volume 16
Issue 7

The National Cancer Institute (NCI) has rejected funding for the proposed P-4 clinical trial in which researchers planned to compare raloxifene (Evista) and letrozole (Femara) as breast cancer prevention agents.

BETHESDA, Maryland—The National Cancer Institute (NCI) has rejected funding for the proposed P-4 clinical trial in which researchers planned to compare raloxifene (Evista) and letrozole (Femara) as breast cancer prevention agents. A letter to officials of the National Surgical Adjuvant Breast and Bowel Project (NSABP) said that "after much deliberation," NCI director John E. Niederhuber, MD, had concluded "that the numerous scientific concerns about the P-4 trial are sufficiently formidable that the NCI will not commit to the funding of this particular trial."

NCI acted 5 days after the National Cancer Advisory Board (NCAB) accepted the report of a working group of its clinical investigations subcommittee that raised significant issues about the trial. Because of cost and other issues confronting the study, "we cannot offer a strong endorsement of this trial," said Bruce A. Chabner, MD, clinical director of the Massachusetts General Hospital Cancer Center, who presented the working group's report to the advisory board.

NSABP envisioned P-4 as a logical extension of previous prevention trials showing positive results with tamoxifen and raloxifene, but the working group pointed out that "despite their ability to decrease the number of tumors by 50%, neither has been widely adopted, probably because of concerns about side effects and the relatively low risk [of developing breast cancer] for a major segment of the female population of interest."

Dr. Chabner told the NCAB: "While the P-4 trial is a well-designed, interesting, and relevant clinical trial, even if positive, we were concerned that it is unlikely to change the practice of clinical oncology."

The P-4 study would have enrolled 12,800 postmenopausal women with a Gail score greater than 1.66 for the 5-year risk of breast cancer. Accrual was to take 4 years, with patients receiving 5 years of treatment, then 3 years of follow-up. The trial's first 5 years would have cost an estimated $54 million.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.